Involving the patient: Impact of inflammatory skin disease and patient-focused care - 21/08/11
Winston-Salem, North Carolina; Portland, Oregon; Irvine, California; and San Francisco, California
Abstract |
Atopic dermatitis (AD) and psoriasis are common chronic inflammatory diseases that are associated with significant psychosocial morbidity and a decrease in health-related quality of life (QOL). To better understand the effects of these two diseases on quality of life, as reported in the literature, a review of all English-language articles from 1970 to 2003 was performed using PubMed. Results from these studies and surveys illustrate the profound negative impact exerted by these conditions and the importance of early and appropriate treatment. These concerns can be incorporated into patient management strategies that focus on a new model for healthcare delivery, “patient-centered care,” in which QOL plays an integral role. The impact of AD and psoriasis on physical, social, psychological, and financial aspects of life should not be trivialized and must be considered with the same importance as other chronic conditions. Because psoriasis and AD are chronic conditions that require patient and/or caregiver involvement for optimal management, the concept of patient-centered care with its emphasis on effective two-way communication is particularly important and useful for the clinician.
Le texte complet de cet article est disponible en PDF.Plan
This article is part of a supplement supported by Connetics Corp, Palo Alto, California. Disclosure: Dr Feldman has received support from Roche, Amgen, Biogen, Bristol-Myers Squibb, Centocor, Fujisawa, Galderma, Genentech, and GlaxoSmithKline and has served as a consultant to Connetics Corp. Drs Behnam and Behnam have no financial interest or competing interests in the subject matter of this article. Dr Koo has been a clinical researcher, consultant, and speaker for Allergan, Amgen, Biogen, Bristol-Myers Squibb, Centocor, Connetics, Elan, Fujisawa, Galderma, Genentech, GlaxoSmithKline, ICN, Novartis, and Roche. The opinions expressed in this article are his own and do not represent the view of any of the companies with which he is affiliated. |
Vol 53 - N° 1S
P. S78-S85 - juillet 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?